SureTrader Advertisement
Home > Boards > US OTC > Medical - Drugs >

Elite Pharmaceuticals (ELTP)

Add ELTP Price Alert      Hide Sticky   Hide Intro
Moderator: Mocha Jet, Drugdoctor, joseytheoutlawwales, lasers, John_Langston, IB_
Search This Board:
Last Post: 7/28/2016 6:22:54 AM - Followers: 832 - Board type: Free - Posts Today: 33

Elite Pharmaceuticals is a specialty pharmaceutical company specializing in niche generics and committed to the development of abuse-deterrent opioids to help curb diversion, misuse and abuse.  Elite has a pipeline of opioid abuse-deterrent products under development utilizing the company’s proprietary pharmacological abuse-deterrent technology.

Elite’s website can be found by going to

How ART Works:

Elite’s proprietary abuse-deterrent technology, ART™, is a multi-particulate capsule which contains an opioid agonist in addition to naltrexone, an opioid antagonist used primarily in the management of alcohol dependence and opioid dependence. When this product is taken as intended, the naltrexone is designed to pass through the body unreleased while the opioid agonist releases over time providing therapeutic pain relief for which it is prescribed. If the multi-particulate beads are crushed or dissolved, the opioid antagonist, naltrexone, is designed to release. The absorption of the naltrexone is intended to block the euphoria by preferentially binding to same receptors in the brain as the opioid agonist and thereby reducing the incentive for abuse or misuse by recreational drug abusers. Elite’s pharmacological approach to abuse-deterrence can be applied to a wide range of opioids used today in pain management.


Recent Press Releases:

Oct 21, 2015
Elite Pharmaceuticals Announces Positive Top-Line Results From a Pivotal Phase 3 Study for Abuse-Deterrent Opioid ELI-200

Aug 10, 2015
Elite Pharmaceuticals Reports Record Revenues for First Quarter of Fiscal Year 2016

Aug 3, 2015
Elite Pharmaceuticals Completes Enrollment and Dosing for ELI-200 Phase III Efficacy Trial

Jun 16, 2015
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology

Jun 9, 2015
Elite Pharmaceuticals and Epic Pharma Enter Into a Sales and Distribution Licensing Agreement for Abuse-Deterrent ELI-200

More information can be found by going to Elite’s investor section:
Highlights From Last Quarter:
Second quarter ending September, 2015
Consolidated revenues for the second quarter of fiscal 2015 was $2.7M, all of which came from Elite's generic operation. An increases of 30% over last quarter's generic revenues. Generic revenue continues to grow with new highs being set  8 out of the 10 last quarters. The cost of revenue for this quarter totals $1.4M, for a gross profit of $1.3M. Overall expenses for the quarter total $5.3M with $4.2M going towards the development of Elite’s proprietary abuse-deterrent opioid product,ELI-200.
Business Update
The first product to utilize Elite's abuse deterrent technology, ELI-200, has successfully completed Phase III studies. The Company believes that it will be able to file a New Drug Application (NDA) with the FDA during this calendar year. When this application is accepted by the FDA it will be granted expedited review by the FDA,the company estimates that approval could be achieved in calender Q2\2016. Shareholders will be notified when the FDA accepts the ELI-200 NDA which is estimated to be in the first or second week in Jan, 2016.
Common shares issued pursuant to the strategic alliance agreement with Epic Investments LLC.
As per the Epic Strategic Alliance, Elite is entitled to 15% of the profits achieved from the commercial sales of Epic's immediate release oxycodone tablets, for a 10 year period commencing on the date of first commercial shipment and Epic is to receive 3 million shares of Common Stock upon approval by the FDA of the ANDA.




President & Chief Executive Officer - Nasrat Hakim

Nasrat Hakim joined Elite in August 2013 as Director, President and Chief Executive Officer. Mr. Hakim has more than 30 years of pharmaceutical and medical industry experience in Quality Assurance, Analytical Research and Development, Technical Services and Regulatory Compliance. He brings with him proven management experience, in-depth knowledge of manufacturing systems, development knowledge in immediate and extended release formulations and extensive regulatory experience of GMP and FDA regulations. Prior to his leading Elite, from 2004 to 2013, Mr. Hakim was employed by Actavis, Watson and Alpharma in various senior management positions. Most recently, Mr. Hakim served as International Vice President of Quality Assurance at Actavis, overseeing 25 sites with more than 3,000 employees under his leadership. Mr. Hakim also served as Corporate Vice President of Technical Services, Quality and Regulatory Compliance for Actavis U.S., Global Vice President, Quality and Regulatory Compliance for Alpharma, as well as Executive Director of Quality Unit at TheraTech, overseeing manufacturing and research and development. In 2009, Mr. Hakim founded Mikah Pharma, LLC, a virtual, fully functional pharmaceutical company.

Mr. Hakim’s career started in Medical Laboratory Technology from the Academy of Health and Sciences in the U.S. Army based in San Antonio, TX, followed by Graduate Certification in Regulatory Affairs (RAC) from California State University at Sacramento, Sacramento, CA; Bachelor in Chemistry/Bio-Chemistry and Masters of Science in Chemistry from California State University at Sacramento, Sacramento, CA; and a Masters in Law with Graduate Certification in U.S. Taxation from St. Thomas University, School of Law, Miami, FL.

Board of Directors Chairman - Jerry Treppel

Mr. Treppel is currently a Managing Director of ArcLight Advisors, an investment bank specializing in the health care sector. From October 2008 through March 2013, Mr. Treppel was Managing Director of Ledgemont Capital Group LLC, a boutique merchant bank that provided access to capital and corporate advisory services to public and private companies. Additionally, he served as the managing member of Wheaten Capital Management LLC, a capital management company focusing on investments in the health care sector from 2003 to 2008. Over the past 20 years, Mr. Treppel was an equity research analyst focusing on the specialty pharmaceuticals and generic drug sectors at several investment banking firms including Banc of America Securities, Warburg Dillon Read LLC (now UBS), and Kidder Peabody and Co. He previously served as a healthcare services analyst at various firms, including Merrill Lynch & Co. Mr. Treppel holds a BA in Biology from Rutgers College, an MHA in Health Administration from Washington University, and an MBA in Finance from New York University. Mr. Treppel has been a Chartered Financial Analyst *CFA) since 1988.

Investor Relations:

Vice President of Investor Relations and Corporate - Dianne Will

Dianne Will joined Elite in 2003 as an Investor Relations Specialist and was named Elite’s Vice President of Investor Relations and Corporate Affairs in 2013. In 1996, Ms. Will founded Willstar Consultants, an investor relations consulting firm and has been providing investor relations services to a range of public companies for more than 19 years with a primary focus in the pharmaceutical and tech sectors. Her firm provides corporate services including management and execution of investor relations programs, investor communication, peer research, compliance services, support for
management team changes, proxy fights, crisis management and IPOs.

Investor Relations and Corporate Inquiries

Dianne Will
Vice President of Investor Relations and Corporate Affairs
Telephone: 518-398-6222

Corporate Headquarters

165 Ludlow Avenue
Northvale, New Jersey 07647
Phone: 201-750-2646
Fax: 201-750-2755

Miscellaneous Links:

SEC Filings:

FDA website:

Clinical Trials.Gov:


  Using the industry average PE\Ratio of 15, an over exaggerated  share count of 100% of the 995M authorized shares, and a very conservative
  profit margin of 30%, Elite stands to garner an increase in share price with the launch of each abuse resistant opioid product.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ELTP News: Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements 07/27/2016 09:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/21/2016 11:47:37 AM
ELTP News: Current Report Filing (8-k) 07/21/2016 07:16:35 AM
ELTP News: Friendable, Inc. (OTC Pink: FDBL) – Ramps Up Infrastructure To Accommodate Growth 07/19/2016 08:00:00 AM
ELTP News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 07/15/2016 05:27:18 PM
News News Alert: Four Trending Stocks Leading Biotech Sector on Heels of Latest R&D and Innovative Drug Therapy Advancements 07/27/2016 09:00:00 AM
#218251  Sticky Note This is not evidence-based medicine. WeeZuhl 07/27/16 03:35:41 PM
#217429  Sticky Note Here is the TRUTH about T-max-SEC-Filed! Drugdoctor 07/25/16 06:43:08 AM
#207474  Sticky Note These people cannot be help by the FDA lasers 06/24/16 06:10:52 PM
#203141  Sticky Note How Pharma Copes with the Pain of Developing Moose45 06/06/16 08:11:20 AM
#200119  Sticky Note Dear WeeZuhl, WeeZuhl 05/15/16 10:56:35 AM
#189564  Sticky Note $ELTP SequestOx and ADF Patents lasers 03/18/16 04:29:26 AM
#185967  Sticky Note The only topic here is ELTP. IH Admin [Dan] 02/23/16 09:32:46 PM
#218445   Total BS. The FDA never said SequestOx wasn't Couch 07/28/16 06:22:54 AM
#218444   Last year's news about the pivotal trial? Lol Didn't namtae 07/28/16 06:18:24 AM
#218443   Is the FDA going to make Elite jump Couch 07/28/16 06:16:31 AM
#218442   Total BS. Couch 07/28/16 06:09:29 AM
#218441   ELTP and the FDA have to get this Couch 07/28/16 06:03:27 AM
#218440   Is there a need? Yes Is opiate abuse a namtae 07/28/16 05:51:35 AM
#218439   Do point out a company in better position? The Bluesummers 07/28/16 05:32:23 AM
#218438   Responsible investing dictates accepting limited risk in highly namtae 07/28/16 04:49:02 AM
#218437   The data doesn't favor Sequest or the FDA namtae 07/28/16 04:40:19 AM
#218436   The FDA fulfilled their obligation to protect the namtae 07/28/16 04:25:43 AM
#218435   Elite can't have the best product on the namtae 07/28/16 04:19:18 AM
#218434   ELTP and the FDA have to get this Bluesummers 07/28/16 03:04:28 AM
#218433   +1 Bluesummers 07/28/16 02:49:16 AM
#218432   Medical professionals have a high degree of respect dr_lowenstein 07/28/16 01:06:42 AM
#218431   k mrwrn2010 07/28/16 12:59:23 AM
#218430   so to be clear that is Nasrat's version dr_lowenstein 07/28/16 12:58:59 AM
#218429   We have the CC transcript filed with the mrwrn2010 07/28/16 12:57:08 AM
#218428   of course we have no proof that is dr_lowenstein 07/28/16 12:55:28 AM
#218427   by the way it is incorrect that the dr_lowenstein 07/28/16 12:53:22 AM
#218426   People with common sense and brains in their mrwrn2010 07/28/16 12:47:11 AM
#218425   I have zero respect for any agency that mrwrn2010 07/28/16 12:44:13 AM
#218424   savvy investors understand that conflicts of interest is dr_lowenstein 07/28/16 12:43:15 AM
#218423   By the way I have to say that dr_lowenstein 07/28/16 12:41:25 AM
#218422   Yeah when you get paid off, I guess mrwrn2010 07/28/16 12:40:19 AM
#218421   at least they got as far as adcom, dr_lowenstein 07/28/16 12:37:24 AM
#218420   Yeah, I'd probably say something similar if I mrwrn2010 07/28/16 12:32:48 AM
#218419   Oh you mean Avridi, which wasn't bioequivalent on mrwrn2010 07/28/16 12:32:12 AM
#218418   LOL LOL yup, the crooked inept FDA. I dr_lowenstein 07/28/16 12:31:21 AM
#218417   Yep, when an FDA AdCom panelist asks questions mrwrn2010 07/28/16 12:28:32 AM
#218416   OH, here is what those FDA crooks said dr_lowenstein 07/28/16 12:27:16 AM
#218415   LOL yeah ok that is convincing, The FDA dr_lowenstein 07/28/16 12:23:55 AM
#218414   Oh I read it. "Background: Opioid overdose continues to mrwrn2010 07/28/16 12:20:12 AM
#218413   Actually you should read that article: dr_lowenstein 07/28/16 12:05:46 AM
#218412   "Alternate literature universe"???? Wtf does that even mean???? The mrwrn2010 07/27/16 11:50:59 PM
#218411   For the elementary school Aqua attended, unsatisfactory performance Aqua 07/27/16 11:34:25 PM
#218410   This is just a highly valuable assessment for COO2002COO 07/27/16 11:23:55 PM
#218409   well where I went to school: dr_lowenstein 07/27/16 10:50:32 PM
#218408   Pinch my butt, I recalled in my elementary Aqua 07/27/16 10:05:12 PM
#218407   AGREED, in many academic institutions, E is a dr_lowenstein 07/27/16 09:59:18 PM
#218406   They should be nicknamed, the "E-Team". Cheers! Aqua 07/27/16 09:52:21 PM
#218405   Camargo?? say isnt that the outfit that told dr_lowenstein 07/27/16 09:49:21 PM
#218404   Based on Mr.Hakim's statements that he expects an LeftySeaTurtle 07/27/16 09:40:47 PM
#218403   Camargo huh..!!!... Nice DD Couch as always. Down Gman24 07/27/16 09:15:37 PM
#218402   Gee and here I was told the FDA Couch 07/27/16 09:09:22 PM
#218401   Oh, I caught that right off the bat... Drugdoctor 07/27/16 08:53:49 PM
#218400   YUP - Notice the document was constructed by Couch 07/27/16 08:52:30 PM
#218399   Very insightful indeed. Looks like the data and RLSJ84 07/27/16 08:51:51 PM
#218398   Nice DD there Couch... A lot of questions Drugdoctor 07/27/16 08:50:31 PM
#218397   ELTP closed under 15 cents today Couch 07/27/16 08:47:26 PM
#218396   And you're not guessing! jtf3 07/27/16 08:46:05 PM